利用靶向LNP/mRNA技术在体内生成功能性、瞬态CAR - T细胞并治疗心脏损伤

The journal of cardiovascular aging Pub Date : 2022-01-01 DOI:10.20517/jca.2022.05

G. Ellison‐Hughes

{"title":"利用靶向LNP/mRNA技术在体内生成功能性、瞬态CAR - T细胞并治疗心脏损伤","authors":"G. Ellison‐Hughes","doi":"10.20517/jca.2022.05","DOIUrl":null,"url":null,"abstract":"Rurik et al. [1] published in Science provide results from an elegant proof-of-concept study that modified messenger RNA (mRNA) encapsulated in targeted lipid nanoparticles (LNPs) can be delivered intravenously to produce functional engineered T cells in vivo . Specifically, they generated transient anti-fibrotic chimeric antigen receptor (CAR) T cells in vivo by delivering modified mRNA in CD5 T cell-targeted LNPs.","PeriodicalId":75051,"journal":{"name":"The journal of cardiovascular aging","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The use of targeted LNP/mRNA technology to generate functional, transient CAR T cells and treat cardiac injury in vivo\",\"authors\":\"G. Ellison‐Hughes\",\"doi\":\"10.20517/jca.2022.05\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Rurik et al. [1] published in Science provide results from an elegant proof-of-concept study that modified messenger RNA (mRNA) encapsulated in targeted lipid nanoparticles (LNPs) can be delivered intravenously to produce functional engineered T cells in vivo . Specifically, they generated transient anti-fibrotic chimeric antigen receptor (CAR) T cells in vivo by delivering modified mRNA in CD5 T cell-targeted LNPs.\",\"PeriodicalId\":75051,\"journal\":{\"name\":\"The journal of cardiovascular aging\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The journal of cardiovascular aging\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.20517/jca.2022.05\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The journal of cardiovascular aging","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20517/jca.2022.05","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

Rurik等人发表在《科学》杂志上的一项优雅的概念验证研究结果表明，包裹在靶向脂质纳米颗粒(LNPs)中的修饰信使RNA (mRNA)可以通过静脉注射在体内产生功能性工程T细胞。具体来说，他们通过在靶向CD5 T细胞的LNPs中传递修饰的mRNA，在体内产生瞬时抗纤维化嵌合抗原受体(CAR) T细胞。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The use of targeted LNP/mRNA technology to generate functional, transient CAR T cells and treat cardiac injury in vivo

Rurik et al. [1] published in Science provide results from an elegant proof-of-concept study that modified messenger RNA (mRNA) encapsulated in targeted lipid nanoparticles (LNPs) can be delivered intravenously to produce functional engineered T cells in vivo . Specifically, they generated transient anti-fibrotic chimeric antigen receptor (CAR) T cells in vivo by delivering modified mRNA in CD5 T cell-targeted LNPs.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

The journal of cardiovascular aging

CiteScore

2.40

自引率

0.00%

发文量